- Patent Title: Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine
-
Application No.: US15411772Application Date: 2017-01-20
-
Publication No.: US10982286B2Publication Date: 2021-04-20
- Inventor: Manish Kohli , Liang Wang , Chiang-Ching Huang
- Applicant: Mayo Foundation for Medical Education and Research, a charitable corporation of Minnesota , The Medical College of Wisconsin, Inc. , UWM Research Foundation, Inc.
- Applicant Address: US MN Rochester; US WI Milwaukee; US WI Milwaukee
- Assignee: Mayo Foundation for Medical Education and Research, a charitable corporation of Minnesota,The Medical College of Wisconsin, Inc.,UWM Research Foundation, Inc.
- Current Assignee: Mayo Foundation for Medical Education and Research, a charitable corporation of Minnesota,The Medical College of Wisconsin, Inc.,UWM Research Foundation, Inc.
- Current Assignee Address: US MN Rochester; US WI Milwaukee; US WI Milwaukee
- Agency: Medlen & Carroll, LLP
- Main IPC: C12Q1/6886
- IPC: C12Q1/6886 ; A61K31/337 ; G16H50/20
Abstract:
The present invention relates to methods of using cell-free DNA analysis for guiding treatment of advanced prostate cancer. In particular, liquid biopsies are collected from urine and/or plasma of patients for measuring copy number variation in cell-free DNA associated with metastatic prostate cancer. In particular, urine genomic abnormality (UGA) and plasma genomic abnormality (PGA) values are contemplated for use in predicting treatment responses in advanced prostate cancer patients and for use in making decisions related to androgen deprivation therapy (ADT) treatment outcomes in hormone sensitive stage and for starting or changing chemotherapy treatments in castrate resistant advanced cancer stage.
Public/Granted literature
Information query
IPC分类:
